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Abstract
The quantification of peptide hormones by means of liquid chromatography
(LC) coupled to mass spectrometry (MS) or other techniques (e.g. immunoassays)
has been a challenging task in modern analytical chemistry. Especially for insulin, its
synthetic analogs, and C-peptide, reliable determinations are urgently needed due to
their diagnostic value in the management of diabetes and insulin resistance and
because of the illicit use of insulin as a performance-enhancing agent in professional
sports or as an effective toxin in forensic toxicology. The concomitant measurement
of C-peptide and insulin offers an established tool for the diagnostic workup of
hypoglycemia (endogenous vs. exogenous hyperinsulinemia), characterizing hepatic
insulin clearance, and the assessment of beta-cell function (insulin secretion). Thus,
the present approach offers the possibility to determine human insulin and its syn-
thetic analogs (lispro, glulisine, aspart, glargine metabolite, degludec, detemir, porcine,
and bovine) and C-peptide simultaneously after sample preparation utilizing protein
precipitation and a mixed-mode cation-exchange solid-phase extraction, and
subsequent detection by LC-high resolution MS. The method was fully validated
regarding the following parameters: specificity, limit of detection (0.2 ng/mL), limit of
quantification (0.6 ng/mL), recovery (40–90%), accuracy (78–128%), linearity, preci-
sion (< 21%), carry over, robustness, and matrix effects. The proof-of-concept was
shown by analyzing authentic plasma samples from adults with class II obesity and
prediabetes collected in the course of an oral glucose tolerance test. All sample
preparation steps were controlled by two stable isotope-labeled internal standards,
namely [[2H10] Leu B6, B11, B15, B17]-insulin, and [[
13C6] Leu 26, 30] C-peptide.
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1 | INTRODUCTION
Insulin is an endogenous peptide hormone having important physi-
ological roles in glucose regulation as well as in energy and ana-
bolic metabolism. C-peptide is produced in equal amounts to
insulin from the same single-chain prohormone (proinsulin) and is
the best measure of endogenous insulin secretion.1 While C-
peptide is a single-chain linear peptide consisting of 31 amino
acids, the structure of insulin is significantly more complex. It con-
sists of two chains (α + β-chain) with three disulfide bridges and
contains a total of 51 amino acids (21 in the α-chain, 30 in the β-
chain). Table 1 shows the amino acid sequence of the two hor-
mones. By equimolar production and release from the pancreas,
the concentration of insulin and C-peptide commonly correlates,
although their plasma half-lives are different. C-peptide is physio-
logically largely inert, does not undergo hepatic first-pass extraction
and therefore persists longer in the circulation, while insulin
exhibits a half-life of only a few minutes.2 The absolute plasma
concentrations for both peptide hormones are in the lower ng/mL
range depending on the blood glucose level, secretory capacity of
the pancreatic beta-cell, and insulin sensitivity.3 Analytically, these
low concentrations in the co-existence of highly abundant plasma
proteins (albumin, IgGs, etc.) represent the particular challenge
in quantitative analysis.4 Existing liquid chromatography/mass
spectrometry-based assays mainly use immunoaffinity-assisted
extraction or other sophisticated isolation techniques for the target
peptides from the matrix.4-9 Other assays using solid phase extrac-
tion strongly focus on insulins (without C-peptide) only.10-12 The
immune-enriched sample aliquots are of highly purified quality,
enabling the injection into nano-scale liquid chromatographs with-
out the risk of blocking due to residual matrix components. The
accomplished specificity of these assays were surpassing, but in
terms of quantification, several issues may arise: Due to the limited
capacity of the antibodies, the linear range of antibody-based
assays is restricted and in the case of co-existing anti-insulin anti-
bodies, which were occasionally described in patients with diabetes
receiving exogenous insulin therapy, the extraction by means of
techniques employing immunoaffinity interaction is potentially
affected.5 Thus, a solid-phase extraction based assay was devel-
oped offering an alternative approach. Herewith, the aforemen-
tioned issues influencing the quantitative result interpretation for
insulin resp. C-peptide analysis should be avoided. Within the pre-
sent approach we aimed to determine human insulin and its syn-
thetic analogs (lispro, glulisine, aspart, glargine metabolite, degludec,
detemir, porcine, and bovine) simultaneously with C-peptide after
sample preparation utilizing a protein precipitation and a mixed-
mode cation-exchange solid-phase extraction and subsequent
detection by liquid chromatography-high resolution mass spectrom-
etry (LC-HRMS). The method enables the quantification of insulin
and C-peptide in physiological non-fasting states with concentra-
tions >0.6 ng/mL. The main characteristics of the target analytes
are summarized in Table 1. Two stable isotope-labeled internal
standards [[2H10] LeuB6, B11, B15, B17]-Insulin (human) and [[
13C6]
Leu26, 30]-C-peptide (human) were used to control all sample prep-
aration steps.
2 | EXPERIMENTAL
Methanol, acetonitrile, glacial acetic acid, dimethylsulfoxide, formic
acid, bovine plasma (EDTA), ammonium hydroxide, porcine insulin,
bovine insulin, and [[13C6] Leu26, 30]-C-peptide (human) were pur-
chased from Sigma (Schnelldorf, Germany). Recombinant human insu-
lin was supplied by Aventis (Kansas City, MO). Solid-phase extraction
cartridges OASIS MCX (30 mg, 3 mL) were bought from Waters
(Eschborn, Germany). All aqueous buffers and solutions were prepared
in MilliQ water. Recombinant human insulin was from Aventis
(Frankfurt, Germany). The labeled insulin standard [[2H10] LeuB6, B11,
B15, B17]-Insulin (human) was purchased from PeptaNova (Sandhausen,
Germany). For all dilution steps and preparation of aqueous solutions,
ultrapure water of MilliQ-quality was used. Insulin analogs lispro
(Humalog®), aspart (Novolog®), glulisine (Apidra®), detemir
(Levemir®), and insulin degludec (Tresiba®) were supplied by Eli Lilly
(Indianapolis, IN), Novo Nordisk (Princeton, NJ), and Aventis (Kansas
City, MO), respectively. The glargine metabolite (DesB31–32 glargine)
was obtained from IBA (Warsaw, Poland). This metabolite was shown
as the main metabolite of insulin glargine.13
2.1 | Blood samples
EDTA-plasma samples were collected from healthy volunteers five
male, five female; without any known medication prior to sampling,
centrifuged and stored frozen until analysis. Additionally, a blood sam-
ple from a patient with type 1 diabetes using basal insulin detemir
(10 IU/d) was analyzed. Another set of samples was obtained from
two adults with class II obesity and pre-diabetes undergoing a 75 g
oral glucose tolerance test with frequent blood sampling at time
points − 15, 9, 10, 20, 30, 60, 90, 120, and 180 min (ongoing clinical
trial, NCT03880162). Written consent from the volunteers and ethical
approval from the local ethical committee of the German Sport Uni-
versity (Cologne) was obtained for the study.
2.2 | Liquid chromatography
Chromatographic separation of the target analytes was conducted
by high performance liquid chromatography (Thermo Vanquish,
Bremen, Germany). Solvent buffers A (aqueous solution of 0.1%
formic acid) and B (acetonitrile with 1% DMSO and 0.1% formic
acid were used for generating the gradient. As the analytical col-
umn, a Poroshell C8 3 × 50 mm (Agilent, Karlsruhe, Germany) was
utilized and the flow was set to 400 μL/min. The gradient started
at 99% A and decreased to 40% A within 8 min. In the next
2 min, the gradient decreased further to 20% A for cleaning.
Finally, the system was re-equilibrated for 4 min at initial condi-
tions. The resulting overall run time was 14 min, and the injection
volume was 20 μL.
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2.3 | Mass spectrometry
A Q Exactive HFX high resolution mass spectrometer (Thermo, Bre-
men, Germany) equipped with a heated electrospray ion source
was used for the analysis of the target peptides. The instrument
was operated in positive ionization mode acquiring data in full scan
mode (m/z = 400–2000, resolution 60 000 FWHM) and targeted
single ion monitoring with data dependent MS2 by means of an
inclusion list. Targeted single ion monitoring experiments (tSIM)
were performed for the multiply protonated precursors of the
target peptides and multiplexed four times with an isolation width
in the quadrupole of 3 Da. The data dependent MS2 experiments
were acquired with a resolution of 15 000 FWHM. As an
alternative to the tSIM experiments, product ion experiments
(PRM) were also performed for the respective five- or four-fold
protonated precursors. The corresponding diagnostic product ions
are listed in Table 1. The instrument was calibrated according to
the manufacturer's recommendations using a calibration mixture
(consisting of caffeine, the tetrapeptide MRFA, and Ultramark). The
gas supply consisted of nitrogen (N2-generator, CMC, Eschborn,
Germany) and was used for all ion source gases and collision gas.
Ionization in positive mode was accomplished at a voltage of
2.5 kV, and the temperature of the transfer capillary was adjusted
to 550C. The main characteristics of the target analytes are
summarized in Table 1.
2.4 | Sample preparation mixed-cation exchange
An ice-cold mixture of 600 μL of acetonitrile/methanol (1:1) was
added to 250 μL of plasma in an Eppendorf tube (not low bind).
After a short vortexing, the tube was centrifuged for 10 min at
17000 × g, and the supernatant was transferred to a new 2 mL
Eppendorf tube. To this tube, 1.4 mL of acetic acid (1%) was added
and vortexed. Solid-phase extraction was performed with mixed-
mode cation-exchange cartridges (Waters MCX, 3 mL, 30 mg)
which were preconditioned with 1 mL of methanol and 1 mL of
water prior to loading with the supernatant from the 2 mL
Eppendorf tube. The samples were washed with 2 mL of water
and 2 mL of methanol (acidified with freshly prepared 2% of acetic
acid). Finally, the sample was eluted to a new 1.5 mL Eppendorf
tube with 1.2 mL of a mixture of methanol/ammonium
hydroxide solution (5:1), and the volume was reduced to near
dryness in a vacuum centrifuge. The dried residue was dissolved in
80 μL of aqueous acetic acid (1%), and 20 μL was injected into the
LC–MS system.
The external calibration curve for quantification was
prepared using commercial bovine EDTA plasma. This plasma
was fortified with all insulin analogs and C-peptide at 0, 0.5,
1, 2, 5, 10, and 20 ng/mL. Aqueous dilutions from the respective
stock solutions (1–14 mg/mL) were not stable and were
prepared freshly in Eppendorf protein-low bind tubes just prior to
fortifying.
2.5 | Validation
The validation of the assay was performed for quantitative purposes
including the parameter specificity, limit of detection (LOD), limit of
quantification (LOQ), linearity, precision, accuracy, recovery, carry-
over, matrix effects, and robustness.
2.5.1 | Specificity
The specificity of the method was demonstrated by 10 blank samples
(EDTA plasma) from 10 healthy volunteers (5 male, 5 female), who
were proven not to have received exogenous insulin. The chromato-
grams were monitored for interfering signals at the respective reten-
tion times.
2.5.2 | Linearity
The linearity and the working range of the method were determined
by a blank matrix spiked with 0, 0.5, 1, 2, 5, 8, 10, and 20 ng/mL of
human insulin, all insulin analogs, and C-peptide. The blank matrix was
bovine plasma (EDTA), which was previously tested for the absence
of all target analytes inclusive of bovine insulin. The linear approxima-
tion was calculated with the respective peak area ratios to the
corresponding internal standard.
2.5.3 | Precision
The precision or variation coefficient of the method was demon-
strated by spiking blank samples at 1 and 5 ng/mL. The precision was
computed under consideration of the peak area ratios to the internal
standard. This experiment was performed on two different days by
different persons (intermediate precision).
2.5.4 | Accuracy
In order to enable quantitative interpretations, the correctness of
the method was verified by determining possible systematic errors.
For this purpose, five spiked blank samples were quantified at
three concentration levels (1, 3, and 8 ng/mL) using an external
calibration curve in bovine plasma. Quantification was performed
considering the peak area ratios using the internal standards and
the external calibration curve. This was followed by the measured
value with the target value.
2.5.5 | Recovery
In order to characterize the losses of analytes during processing, the
recovery was determined at 10 ng/mL. For this purpose, six negative
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control samples were spiked before processing and six further sam-
ples were spiked after processing shortly before injection into the LC–
MS. The comparison of the results using the peak area ratios to the
internal standard provided information on the recovery of the
method.
2.5.6 | Carry-over
A possible carry-over of analyte from one sample to the next was
investigated by injecting a negative control sample after a spiked sam-
ple from the upper working range (20 ng/mL) and inspecting the
respective chromatograms for possible carry-over signals.
2.5.7 | Matrix effect
The comparison of the signal intensities of five processed negative
control samples that were subsequently spiked with all target analytes
with a standard sample that did not contain any matrix was used to
determine the matrix effects. This strategy is described in detail
elsewhere.14
2.5.8 | Robustness
Fortified samples (at 10 ng/mL) of EDTA-, citrate-, heparin-plasma
as well as serum (two samples each) were prepared and
analyzed as described above. All these samples were evaluated
for potential additional interfering signals at the respective
retention times.
3 | RESULTS
3.1 | Liquid chromatography/mass spectrometry
Within the 14 min analytical run, all target analytes were detected
resulting in acceptable peak shapes. Figure 1 shows an example of
a blank sample with endogenous human insulin and C-peptide only
(Figure 1) and a fortified sample at 0.6 ng/mL (Figure 2). As
expected, the synthetic analogs comprising a fatty acid (insulin
degludec 8.3 min and insulin detemir 9.2 min) eluted significantly
later. Noteworthy, although all other insulins exhibited similar
retention times, the minor retention time shifts are reproducible
and characteristic. This was already shown in former studies.15 In
addition to the diagnostic ion traces in the respective SIM experi-
ments, data dependent MS/MS spectra supported the detection
and confirmed the identification of the insulins. This is especially
true for the differentiation of human insulin and insulin lispro,
which present identical molecular masses. Here the monitoring of
the MS/MS experiment at m/z 1162 or 1452 is crucial for all sam-
ples. As described earlier, human insulin shows a diagnostic product
ion at m/z 226 (y3-y1), insulin lispro yields an ion at m/z 217 as
the most abundant product ion.16
3.2 | Validation
Full method validation was performed for quantitative analysis. The
main results are summarized in Table 1. The verification of the
specificity demonstrated, when measuring plasma samples of
healthy volunteers, that the method showed no interfering signals
in the ion traces of the individual analytes at the corresponding
F IGURE 1 Extracted ion chromatograms of a blank sample from a healthy volunteer showing signals for endogenous human insulin and C-
peptide only
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F IGURE 2 Extracted ion chromatograms of a human blank sample fortified at the LOQ with 0.6 ng/mL (except 1 ng/mL for detemir) for all
insulin analogs. C-peptide is endogenous and was not fortified
F IGURE 3 Extracted ion chromatograms of a
post administration sample from a patient
suffering from diabetes mellitus (type I) with a
regular treatment of insulin detemir. Besides the
detection of insulin detemir at 9.17 min, no
endogenous C-peptide as well as no endogenous
human insulin was detected in this sample
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retention times (Table 2). Only human insulin and C-peptide were
detectable at endogenous levels. The limits of detection ranged at
approximately 0.2 ng/mL for all target analytes (only the LODs for
insulin detemir and insulin degludec were estimated at 0.5 ng/mL),
which is sufficient to monitor normal to non-fasting levels in blood.
In six out of six fortified blank samples at 0.2 ng/mL (0.5 ng/mL),
the target analytes were detected with a signal-to-noise (S/N) > 3.
At the limit of quantification (1 ng/mL), the S/N was > 9 and the
coefficient of variation (six-fold determination of fortified blank
sample pool) for all target analytes was better than 21%. Within
the aimed working range (0–10 ng/mL), linear approximation shows
acceptable results with a coefficient of correlation r > 0.985. The
accuracy indicates no systematic bias for the assay with
results ranging from 76% to 128% at 1 ng/mL and between 77%
and 108% at 5 ng/mL. The recoveries ranged at about 50%
(38–57%) for all insulins and at 92% for C-peptide. Under the
chosen chromatographic conditions and within the working
range (up to 20 ng/mL), no carry-over was observed. Ion
suppression or enhancement effects for different blank samples
were monitored and resulted in considerable variation of signal
intensity at approximately 60–120%. While these effects are ideally
compensated for by labeled ISTDs for human insulin and C-peptide,
this is also true (to a lesser extent) for all insulins, which elute at
about 7 min. Here, a sub-optimal ISTD-compensation is obtained
for the late eluting insulin detemir/degludec, yielding significantly
higher coefficients of variation (precision), lower coefficients of
correlation, and inferior accuracies. The analysis of different
sample matrices (EDTA, heparin, citrate or serum) for robustness
showed that in principle any of these matrices can be used.
The signal intensities showed comparable results for all of these
fortified samples.
3.3 | Proof of concept
In Figure 3, extracted ion chromatograms of a post administration
blood sample are shown, which indicate the proof of concept of
the method under authentic conditions. These obtained results are
in accordance with the patient's daily injection dose of the syn-
thetic insulin analog detemir. Additionally, plasma samples from
two adults with class II obesity and prediabetes undergoing an oral
glucose tolerance test (oGTT) were measured. Insulin and C-peptide
concentrations were calculated with an external calibration curve in
bovine plasma at 0, 0.5, 1, 2, 5, and 10 ng/mL for human insulin
and 0, 1, 2, 10, and 20 ng/mL for C-peptide. Figure 4 shows the
insulin and C-peptide concentrations in ng/mL starting from −15
to 180 min after oGTT for two adults with class II obesity and pre-
diabetes. The basal insulin levels start at 0.2 ng/mL, peak after
90 min at approximately 4 ng/mL, and decrease to 0.5 ng/mL after
180 min. C-peptide starts at about 4 ng/mL, increases to approx.
16 ng/mL after 90 min before decreasing to 6 ng/mL at 180 min.
The results presented here are in good accordance with the
established data.17 T
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4 | CONCLUSION
Although the obtained results are very promising, there are limitations
that must be taken into account in order to avoid misinterpretations
and false expectations. For example, it is known that hemolyzed sam-
ples (plasma or serum) lead to major problems, which are caused on
the one hand by the considerable disturbance of ionization (matrix
effects) and on the other hand by the previously described degrada-
tion of insulin in the presence of hemoglobin.18
Another aspect is the modest specificity of the sample prepara-
tion, which in principle enriches all peptidic analytes more or less
well from the blood sample. Here, antibody-based sample prepara-
tions have considerable advantages and should always be performed
additionally to confirm the qualitative presence of the respective
insulin.19,20 The present approach offers advantages in terms of
lower costs and simplicity. Furthermore, the aforementioned incom-
patibility of the method with nano-scale LC systems limits the
accomplished sensitivity, which would also be necessary to compre-
hensively cover fasting states (< 0.2 ng/mL) of insulin in the
circulation.
Finally, the quantification performance for insulin detemir and
insulin degludec is significantly lower, which is most likely due to the
impaired ISTD-compensation for these late eluting acylated synthetic
analogs. This was also seen in earlier studies.5 Whether the yielded
results are still in the acceptable range, strongly depends on the aimed
requirements. Considering the mentioned limitations, a comparison of
this method with earlier published assays showed that the present
method is to some extent less sensitive, but by using high resolution
mass spectrometry the qualitative (and quantitative) result interpreta-
tion is very strong.5,11,12,21,22 Additionally, the simultaneous determi-
nation of C-peptide in the same assay enables a more comprehensive
result.
In summary, the method shown here can be used reliably for the
quantification of insulin and its synthetic or animal analogs and C-
peptide in blood samples (plasma and serum). In comparison with
earlier methods, this simplified sample preparation approach allows
for a faster and straight-forward testing method, which shows an
improved upper dynamic range in comparison with antibody-based
procedures, especially at concentrations in moderate ng/mL levels.
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